drugset / Trial / NCT00302172
ARQ 197 in Subjects With Metastatic Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197.
Timeline
- Start
- 2006-01
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tivantinib | Small molecule | 10 mg | Oral |
| Subject | Tivantinib | Small molecule | 360 mg | Oral |